Comparative Effectiveness and Safety of FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Metastatic Colorectal Cancer: A GRADE-assessed Systematic Review and Meta-analysis.
Ahmed Raza, Maria Qadri, Faiza Fatima et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the effectiveness and safety of FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab in 561 patients with metastatic colorectal cancer (mCRC). The study found no significant differences in overall survival (HR: 1.22; 95% CI: 0.78 - 1.90; p = 0.386) or progression-free survival (HR: 1.32; 95% CI: 0.76-2.31; p = 0.324) between the two treatment regimens.
Key findings
- Overall survival did not differ significantly between FOLFOXIRI-cetuximab and FOLFOXIRI-bevacizumab (HR: 1.22; 95% CI: 0.78 - 1.90; p = 0.386).
- Progression-free survival also showed no significant difference (HR: 1.32; 95% CI: 0.76-2.31; p = 0.324).
- Cetuximab was associated with significantly higher rates of hypomagnesemia and acneiform rash (p < 0.01).
- No significant differences were found in objective response rates or depth of response.
Why it matters
Understanding the comparative effectiveness and safety of treatment options for metastatic colorectal cancer is crucial for optimizing patient outcomes. This study highlights that while both combinations are similar in efficacy, they differ in safety profiles, which can influence treatment decisions.